Screener
Charles River Laboratories CRL Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | June 27, 2026 | December 27, 2025 |
|---|---|---|
| Deferred revenue | 203,035 | 210,418 |
| Accrued liabilities | 380,101 | 270,085 |
| Other current liabilities | 222,792 | 222,158 |
| Total current liabilities | 1,134,746 | 1,120,315 |
| Long-term debt, net and finance leases | 2,619,985 | 2,136,360 |
| Operating lease right-of-use liabilities | 407,708 | 434,048 |
| Deferred tax liabilities | 78,668 | 95,203 |
| Other long-term liabilities | 402,511 | 138,302 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's total current liabilities?
- Charles River Laboratories (CRL) reported total current liabilities of $1.13B in Q2 2026.
- How has Charles River Laboratories's total current liabilities changed year-over-year?
- Charles River Laboratories's total current liabilities increased by 5.0% year-over-year, from $1.08B to $1.13B.
- What is the long-term trend for Charles River Laboratories's total current liabilities?
- Over 5 years (2020 to 2025), Charles River Laboratories's total current liabilities has grown at a 5.9% compound annual growth rate (CAGR), from $839.75M to $1.12B.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Charles River Laboratories's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude